Moon Surgical is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room. The Maestro System from Moon Surgical, provides complete control, fresh trust, and technology that can adapt to every condition faced, resulting in increased operating room efficiency and surgical care for patients. Moon Surgica is employing tomorrow's technology to alter surgery today.
Cara Care is a digital gut health platform that offers an app-based treatment to help patients with chronic gastrointestinal problems. It empowers patients suffering from chronic digestive diseases to enjoy a better life. Cara Care takes digestive health beyond the pill, bringing together behavioral, microbial, and nutritional data. Cara Care has already helped 700.000+ patients around the world with software-based medical devices.
Moon Surgical is a medical device company developing a surgical robot for laparoscopy assistance. MastOR is an early-stage surgical robotics company whose laparoscopy assistance platform broadens access to minimally-invasive techniques for surgeons and optimizes resource utilization in the operating room. The Maestro System from Moon Surgical, provides complete control, fresh trust, and technology that can adapt to every condition faced, resulting in increased operating room efficiency and surgical care for patients. Moon Surgica is employing tomorrow's technology to alter surgery today.
Enhanc3D Genomics is a functional genomics firm that studies the three-dimensional organization of DNA in health and disease. The company's GenLink3D platform helps comprehend the impact of such mutations on distant genes, thereby revealing how they influence disease progression.
Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.
Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform. While DNA can reveal biological insights, proteins provide the actual insights into the functions of our bodies. The company is in the process of developing a pioneering, next-generation protein sequencing platform that will empower researchers to acquire unprecedented insights into both biology and diseases.
TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.
DERMALA is a consumer dermatology company leveraging scientific understanding of the human microbiome and data analytics to develop personalized, clinically validated, patented treatments for chronic skin conditions including acne and eczema. The company’s #FOBO® (Fear of Breaking Out) system, a personalized microbiome-based solution for acne, combines patented topical acne treatments and oral supplements with a proprietary DERMALA Acne Tracker app that customers use to track their skin health and get their treatment optimized monthly. For more information, visit dermala.com.
XW Laboratories is an Asia-Pacific biopharmaceutical company dedicated to discovering and developing transformational medicines that will markedly improve the quality of life in patients suffering from neurological disorders. Founded in 2014, XW Laboratories has developed 3 unique drug R&D platforms that not only allow us to improve upon existing medication through approaches such as prodrug and functional group switch, but also be at the forefront of medicinal technology in immunoneurology through the application of their mitochondria-targeting platform.
2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.
Legend Biotech is a clinical-stage biopharmaceutical company that discovers and develops novel cell therapies for oncology. The company develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Its initial product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma.
Adicet Bio is a biotechnology company engaged in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.
Carbon provides printing solutions for products that outperform. The company helps businesses develop better products and bring them to market in less time. Carbon is a venture-backed company. They serve industries including automotive, consumer, industrial, life sciences, and dental.
Artizan Biosciences provides pharmaceutical drug development services, namely, the development of small molecule drugs for use in humans. The Durham-based biotech company declined to disclose its intended use of the proceeds from this offering, as well as its current revenue range.
TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoring capabilities, causing high failure rates. Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures.
Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
Hyalex Orthopaedics is a Lexington, MA medical device company advancing new products that feature HYALEX™ materials technology, a polymer that is designed to mimic cartilage. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. Hyalex Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated.
Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.
BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.
Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.
Magnolia Neurosciences aims to discover and develop proprietary, selective, and drug-like small molecule therapeutics for the prevention of neuronal cell death, thereby providing novel treatment options for patients suffering from neurodegeneration and related conditions. Magnolia Neurosciences Corporation, created to pursue technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium (NDC), is a New York-based Accelerator Life Science Partner portfolio company.
V-Wave is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity, and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing, and bringing to market multiple implantable cardiovascular devices.
Osteal Therapeutics is a clinical-stage specialty pharmaceutical company developing novel drug and device combination products for treating musculoskeletal infection.
RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency.
EpigenCare is connecting consumers with skincare companies through a direct-to-consumer skincare test and web platform on the Ethereum network. Consumers receive actionable recommendations of optimized skincare products to use, as well as assess the progress of their skincare routines, based on their skin's epigenetic profiles. The recommendation engine looks at the functional state of a panel of epigenetic markers strongly correlated with skin quality indicators (e.g., aging, moisture retention, elasticity, etc.), and how skincare product ingredients affect them. It offers SKINTELLI, a direct-to-consumer personal epigenomics test that measures DNA methylation levels of a proprietary panel of genes responsible for key skin quality factors (e.g., aging, elasticity, moisture retention, etc.). The SKINTELLI web platform empowers you with the knowledge of which products truly work for your skin. EpigenCare was founded in 2017 and based in Farmingdale, New York.
Carbon provides printing solutions for products that outperform. The company helps businesses develop better products and bring them to market in less time. Carbon is a venture-backed company. They serve industries including automotive, consumer, industrial, life sciences, and dental.
Certa Dose is a medical device company that offers an intuitive system that uses color confirmation to deliver accurate dosing. Its first product is a U.S. Food and Drug Administration-cleared syringe for use with the administration of epinephrine to pediatric patients. Each syringe is labeled with easy to recognize color zones that match the industry-standard Broselow pediatric color-coding system to help clinicians verify the correct dose during critical, time-sensitive situations. Users match the patient to a zone on the color scale and administer the medication to the corresponding color on the Certa Dose syringe. The patented syringe incorporates the right dose, the right concentration, and the right route of administration of medication dosing, along with a color-matching technology that creates an easy-to-use system focused on saving children’s lives by curbing critical medication errors
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company. It is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production center. Fusion’s deep radiochemistry expertise presents a technology platform that can be replicated to turn internalizing antibodies that have previously demonstrated limited clinical efficacy into highly effective cytotoxic drugs. Fusion’s ability to link effective isotopes to the targeting antibody allows for the creation of optimized agents for both diagnostic imaging and radioimmunotherapy (Precision Medicine). Following positive tumor identification with the imaging agent, treatment with the antibody linked to a therapeutic isotope delivers a cytotoxic payload into the cancer cell. Fusion’s lead product candidate, FPX-01, is a precision RIT that is a product of this innovative approach. FPX-01 has been designed to internalize targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody causes selective and extremely effective cytotoxicity of tumor cells at relatively low doses of radioactivity.
XW Laboratories is an Asia-Pacific biopharmaceutical company dedicated to discovering and developing transformational medicines that will markedly improve the quality of life in patients suffering from neurological disorders. Founded in 2014, XW Laboratories has developed 3 unique drug R&D platforms that not only allow us to improve upon existing medication through approaches such as prodrug and functional group switch, but also be at the forefront of medicinal technology in immunoneurology through the application of their mitochondria-targeting platform.
Rodeo Therapeutics is a drug development company focused on novel enzyme target and biological pathway that play a critical role in tissue repair and regeneration. Rodeo’s initial goal is to develop novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant.
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.
Hyalex Orthopaedics is a Lexington, MA medical device company advancing new products that feature HYALEX™ materials technology, a polymer that is designed to mimic cartilage. Unlike other polymers, synthetic HYALEX material has the unique capability of maintaining low friction and low wear under the high loads encountered in human joints. Hyalex Orthopaedics' products are in the development stage and have not been approved for use in humans by any regulatory agency.
BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.
The SuperX team is engaged in the discovery of antibodies against an undisclosed target in the blood coagulation cascade. SuperX hopes to reach the clinic in 2019.A preclinical stage biopharmaceutical company, based at Babraham Research Campus, developing novel anticoagulant drugs
Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses. Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.
Binx Health is committed to broadening convenient and equitable access to healthcare. The company's point-of-care diagnostic solutions empower its partners to overcome traditional barriers to care, extend their outreach, and deliver exceptional patient experiences. The binx io point-of-care molecular platform marks a significant milestone as the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males (urine) and females (vaginal swabs). It delivers results comparable to those of central lab performance, typically within about thirty minutes.
OrthoSpace develops and commercializes simple-to-implant, biodegradable balloon systems for the orthopaedic market. The company aims to create effective solutions for orthopaedics that reduce pain and increase patients’ range of motion while preserving patient bone and joint structures. The company’s first product has the CE mark and is currently marketed in Europe. InSpace™ is indicated for patients who suffer from rotator cuff injury, reducing shoulder pain and improving range of motion.
Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. The company's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development, shares in the cost and risk of clinical development, and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States.
Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota.
RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency.
Welldoc develops technology solutions to support chronic disease management. They work with leaders across the healthcare, life science, and medical device industries to ensure the solutions they develop scale and integrate into their existing workflows and systems. The Welldoc platform offers support for multiple chronic conditions, ecosystem solutions, and artificial intelligence.
Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated.
Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of naturally derived novel therapeutics that will have a dramatic impact human health on a global basis. Lodo seeks to work in partnership with global pharmaceutical companies and world leading Non-Governmental Organizations (NGO’s) to tackle some of the greatest challenges in human health: resistant infectious disease and cancers. Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University. Dr. Brady and his laboratory have developed a genome-based, culture-independent platform for the discovery, biosynthesis, and characterization of small molecules from microbial sources present in soil samples. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. By combining the advancements in DNA sequencing and bioinformatics, this innovative discovery platform exploits the power of microbial evolution for the identification of therapeutically valuable pharmaceutical products derived from natural sources. Lodo Therapeutics, an Accelerator Corporation-backed entity, is headquartered in New York City. The company’s lab and offices are located in the Alexandria Center for Life Science, New York City’s first and only premier life science park.
V-Wave is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity, and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing, and bringing to market multiple implantable cardiovascular devices.
Aelix Therapeutics develops therapeutic vaccines and immunotherapies to treat HIV infection. The company is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was created under the leadership of its founders, Dr. Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Mr. Jordi Naval; all of whom have several decades of experience in HIV and biotech development. The company’s know-how will further expand through unique immunogen designs. It will also benefit from ready access to large cohorts of HIV infected patients in several continents through its partnership with the HIVACAT consortium.
Petra Pharma is a clinical-stage pharmaceutical company developing a diverse portfolio of novel therapies for serious medical conditions such as cancer and metabolic diseases. The company also focused on novel enzyme targets that play a central role in a variety of important cellular processes, including cell division, growth, trafficking, and signaling. It will develop novel small molecules for the treatment of cancer and metabolic diseases to target these cellular processes in order to therapeutically impact human health. Petra Pharma was founded in 2016 and is headquartered in New York, USA.
Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.
First Aid Shot Therapy offers a market segment defined as clinical beverages designed to address acute or chronic clinical needs. It offers a range of easy-to-swallow, single-dose products that provide fast-acting relief for most common everyday symptoms; hangover, pain, sleep, cold, allergy, and heartburn. The company was founded in 2010 and is headquartered in Burlingame, California.
PrEP Biopharm is a biopharmaceutical company. That focused on the prevention of respiratory infections. They prevent upper respiratory tract viral infections. PrEP-001 is a phase 2 nasal spray that increases the host's innate immune response and protects against all respiratory viruses and is predicted to be used to combat respiratory viral pandemics such as COVID-19.
Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone.
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with innovative mechanisms of action.
DJS Antibodies is developing novel therapeutics to treat chronic inflammatory diseases. DJS does this through the discovery and development of novel therapeutic monoclonal antibodies against GPCRs. The company's breakthrough technology enables its to produce first-in-class antibody therapeutics to previously intractable disease targets.
Binx Health is committed to broadening convenient and equitable access to healthcare. The company's point-of-care diagnostic solutions empower its partners to overcome traditional barriers to care, extend their outreach, and deliver exceptional patient experiences. The binx io point-of-care molecular platform marks a significant milestone as the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males (urine) and females (vaginal swabs). It delivers results comparable to those of central lab performance, typically within about thirty minutes.
XW Laboratories is an Asia-Pacific biopharmaceutical company dedicated to discovering and developing transformational medicines that will markedly improve the quality of life in patients suffering from neurological disorders. Founded in 2014, XW Laboratories has developed 3 unique drug R&D platforms that not only allow us to improve upon existing medication through approaches such as prodrug and functional group switch, but also be at the forefront of medicinal technology in immunoneurology through the application of their mitochondria-targeting platform.
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuries to joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach.
CartiHeal, a privately held medical device company headquartered in Israel, is a pioneer in the field of cartilage regeneration. Cartilage injuries affect millions of patients around the world, and characteristically cause severe pain and disability. Hyaline cartilage has a very limited ability to heal once damaged. Research indicates that injuries to joint cartilage, if left untreated, may lead to progressive joint changes and early onset of osteoarthritis. The need for a simple, well-tolerated and effective solution for cartilage repair and regeneration represents one of medicine’s most challenging unmet needs. CartiHeal's flagship Agili-C™ implant represents a significant medical breakthrough. This implant has shown to promote regeneration of true hyaline cartilage and its subchondral bone, simultaneously without the use of cells, growth factors or other exogenous agents. The cell-free implant is inserted arthroscopically or via a minimally-invasive approach.